Finance

Lists
GRDN:NYSE
Guardian Pharmacy Services Inc
$44.99
-0.13%
(-0.060) 1D
$44.99
0.00% (0.00)
After hours
Closed: Sep 18, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GRDN...
Open
$45.01
High
$45.64
Low
$44.24
Mkt. cap
2.85B
Avg. vol.
498.97K
Volume
3.21M
P/E ratio
44.03
52-wk high
$48.33
52-wk low
$23.14
EPS
$1.02
Shares outstanding
49.80M
No. of employees
4K
Open
$45.01
High
$45.64
Low
$44.24
Mkt. cap
2.85B
Avg. vol.
498.97K
Volume
3.21M
P/E ratio
44.03
52-wk high
$48.33
52-wk low
$23.14
EPS
$1.02
Shares outstanding
49.80M
No. of employees
4K
News stories
From web sources and news partners
About Guardian Pharmacy Services Inc
CEO-
Employees3.6K
Founded2003
HeadquartersAtlanta, Georgia, United States
SectorHealth care provider
Websiteguardianpharmacy.com
Analyst ratings
Based on 4 analysts giving stock ratings to GRDN in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for GRDN in the last 3 months.
Highest
Current $44.99
$50.00 (+11.14%)
Average
$48.67 (+8.18%)
Lowest
$47.00 (+4.47%)
Analyst
Recommendation
Action
Price target
Projected
Date
Allen Lutz
Bank of America Securities
Buy
Reiterated
$47.00
+4.5%
09/01/2026
David S Macdonald
Truist Financial
Buy
Reiterated
-
-
08/07/2026
Michael Wiederhorn
Oppenheimer
Buy
Maintained
$49.00
+8.9%
08/07/2026
Unknown Analyst
Stephens
Buy
Reiterated
$50.00
+11.1%
08/07/2026
Richard Newitter
Truist Financial
Buy
Maintained
$47.00
+4.5%
06/22/2026
Brian Tanquilut
Jefferies
Buy
Reiterated
$50.00
+11.1%
06/15/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.29 / $0.27
+8.08%beat
Revenue / Est. (USD)
351.77M / 339.99M
+3.46%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
377.43M
397.62M
336.60M
351.77M
Cost of goods sold
302.71M
312.11M
260.29M
271.72M
Cost of revenue
302.71M
312.11M
260.29M
271.72M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
57.82M
50.14M
55.43M
67.80M
Operating expense
57.82M
50.14M
55.43M
67.80M
Total operating expenses
360.53M
362.25M
315.72M
339.53M
Operating income
16.90M
35.37M
20.88M
12.24M
Other non operating income
437.00K
500.00K
772.00K
9.30M
EBT including unusual items
16.63M
31.10M
18.29M
29.79M
EBT excluding unusual items
17.18M
35.70M
21.50M
21.39M
Income tax expense
7.04M
9.83M
4.75M
7.67M
Effective tax rate
42.32%
31.62%
25.96%
25.75%
Other operating expenses
-
-
-
-
Net income
9.82M
20.92M
13.30M
21.87M
Net profit margin
2.60%
5.26%
3.95%
6.22%
Earnings per share
0.25
0.37
0.29
0.29
Interest and investment income
-
-
-
-
Interest expense
-160.00K
-163.00K
-154.00K
-154.00K
Net interest expenses
-160.00K
-163.00K
-154.00K
-154.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
22.74M
41.11M
26.85M
18.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps